Genmab — November 2013
-
-
fastholder fye
-
det regnskab ligner selve definitionen af et non-event
-
well, david opjusterede de facto i løbet af CC og Jan lovede guld og grønne skove ifm offentliggørelsen af ASH Abstracts i morgen kl 1500 dansk tid
-
så selv om regnskabet ikke havde det store schwung, så kan der godt komme til at ske ting og sager i morgen
-
pfs på ga101 er i øvrigt blevet opjusteret til 26,7 måneder - https://ash.confex.com/ash/2013/webprogram/Paper60276.html
-
på alle måder en dårlig GEN dag
-
men det jeg slet ikke fanger er, hvorfor får arzerra BTD? Der må være noget, jeg ikke kan se
-
Jeg tror, at vi skal holde ekstra godt øje med insidersalg de næste par uger. Vinduet må være åbent nu
-
Selvfølgelig skal Arzerra have BTD: Investigator-assessed ORR was 95% (CR rate 43%) in the previously
untreated population and 74% (CR rate 11%) in the relapsed
population. 56% of patients in the in the previously untreated
population who had an investigator-assessed CR and had MRD analysis
performed were MRD negative at the 3-month follow-up visit -
Alle glemte i dag, at det ikke kun handler om OC, men om http://files.shareholder.com/downloads/AMDA-KPIBN/2774297033x0x689456/E648D1D6-1935-44B9-8017-69783BBE0402/2013_IWCLL_ofa_991_CLL_Offner_poster_FINAL.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind